Health ❯ Healthcare ❯ Oncology

Clinical Trials

Patient Outcomes Adverse Effects Phase 2 Trials Phase 3 Trials Phase II Trials Bladder Cancer Precision Medicine Metastatic Castration-Sensitive Prostate Cancer Trial Results Health-Related Quality of Life Pancreatic Cancer Silevertinib Lung Cancer EGFR L858R-Mutated NSCLC Mantle Cell Lymphoma Abstracts ESMO Congress 2025 Non-Small Cell Lung Cancer DESTINY-Breast05 Trial Breast Cancer HER2-positive Breast Cancer Metastatic Colorectal Cancer Gastroenteropancreatic Neuroendocrine Tumors Combination Therapies Treatment Efficacy Drug Treatments ADRIATIC Trial Small Cell Lung Cancer IMforte Trial NRG-LU005 Study Immunotherapy Regorafenib Glioblastoma Patient Response Temozolomide Cancer Research Emerging Therapies Phase I Trials

Silevertinib Delivers 60% Response and Strong CNS Activity in First-Line NSCLC With Non-Classical EGFR Mutations

Black Diamond said the results underpin a randomized glioblastoma study slated for 2026, with progression-free survival readouts in NSCLC still to come.

mRNA COVID Vaccination Linked to Longer Survival With Cancer Immunotherapy, Data Presented at ESMO

ASCENT-03 Finds Sacituzumab Govitecan Extends PFS Over Chemotherapy in First-Line PD-L1–Negative TNBC

Padcev–Keytruda Cuts Recurrence and Death Risk in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer